Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Buck

Showing results (231-240 of 400) with videos related to

Pageof 40
Sort By:
Oncotarget|June 4, 2016
The impact of 177Lu-octreotide therapy on 99mTc-MAG3 clearance is not predictive for late nephropathyRudolf A Werner, Seval Beykan, Takahiro Higuchi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 2, 2007
Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLTAndreas K Buck, Clemens Kratochwil, Gerhard Glatting, et al.
Leukemia & Lymphoma|July 8, 2022
CXCR4 expression of multiple myeloma as a dynamic process: influence of therapeutic agentsAnna Bögelein, Antje Stolzenburg, Patrick Eiring, et al.
Clinical Nuclear Medicine|November 10, 2022
Impact of 68 Ga-FAPI-04 PET/CT on Staging and Therapeutic Management in Patients With Digestive System TumorsAleksander Kosmala, Sebastian E Serfling, Wiebke Schlötelburg, et al.
Medicine|November 13, 2015
Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib TreatmentR A Werner, J S Schmid, D O Muegge, et al.
Clinical Nuclear Medicine|March 5, 2025
Myeloablative Radioligand Therapy Targeting C-X-C Motif Chemokine Receptor 4 in Advanced Multiple MyelomaNiklas Dreher, Anna-Lena Dörrler, Sabrina Kraus, et al.
Theranostics|January 8, 2019
The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?Rudolf A Werner, Alexander Weich, Malte Kircher, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 9, 2015
iROLL: does 3-D radioguided occult lesion localization improve surgical management in early-stage breast cancer?Christina Bluemel, Andreas Cramer, Christoph Grossmann, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 18, 2008
SPECT/CTAndreas K Buck, Stephan Nekolla, Sibylle Ziegler, et al.
Molecular Imaging and Biology|May 4, 2026
Diagnostic Performance of Somatostatin Receptor-directed PET/CT for Tumor-induced OsteomalaciaMarieke Heinrich, Aleksander Kosmala, Alexander Dierks, et al.
Pageof 40

Showing results (231-240 of 400) with videos related to

Sort By:
Pageof 40
Oncotarget|June 4, 2016
The impact of 177Lu-octreotide therapy on 99mTc-MAG3 clearance is not predictive for late nephropathyRudolf A Werner, Seval Beykan, Takahiro Higuchi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 2, 2007
Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLTAndreas K Buck, Clemens Kratochwil, Gerhard Glatting, et al.
Leukemia & Lymphoma|July 8, 2022
CXCR4 expression of multiple myeloma as a dynamic process: influence of therapeutic agentsAnna Bögelein, Antje Stolzenburg, Patrick Eiring, et al.
Clinical Nuclear Medicine|November 10, 2022
Impact of 68 Ga-FAPI-04 PET/CT on Staging and Therapeutic Management in Patients With Digestive System TumorsAleksander Kosmala, Sebastian E Serfling, Wiebke Schlötelburg, et al.
Medicine|November 13, 2015
Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib TreatmentR A Werner, J S Schmid, D O Muegge, et al.
Clinical Nuclear Medicine|March 5, 2025
Myeloablative Radioligand Therapy Targeting C-X-C Motif Chemokine Receptor 4 in Advanced Multiple MyelomaNiklas Dreher, Anna-Lena Dörrler, Sabrina Kraus, et al.
Theranostics|January 8, 2019
The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?Rudolf A Werner, Alexander Weich, Malte Kircher, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 9, 2015
iROLL: does 3-D radioguided occult lesion localization improve surgical management in early-stage breast cancer?Christina Bluemel, Andreas Cramer, Christoph Grossmann, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 18, 2008
SPECT/CTAndreas K Buck, Stephan Nekolla, Sibylle Ziegler, et al.
Molecular Imaging and Biology|May 4, 2026
Diagnostic Performance of Somatostatin Receptor-directed PET/CT for Tumor-induced OsteomalaciaMarieke Heinrich, Aleksander Kosmala, Alexander Dierks, et al.
Pageof 40